Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Sep 28, 2010

Premium

Silicon Kinetics this week launched its SKi Pro X1000, a biosensor instrument that supports label-free interaction analysis.

The San Diego-based firm said the new system supports experiments in multiwell plates and fine kinetic measurements in flow cells using the same reader instrument and surface chemistry.

With integrated robotics, the system also automates experiments in a 96-well plate, the firm claimed.


Genedata this week began selling its Expressionist Refiner Genome module, a software tool for analyzing sequencing and array data.

Relying on a genomic browser capable of visualizing terabytes of data, the module enables whole-genome analysis including transcriptome, DNA methylome, gene regulation, copy number variation, and SNP genotyping studies.

According to Genedata, the module can analyze data in such combinations as next-generation sequencing with microarray data, transcriptomics data with DNA methylation data, small RNA data with gene expression data, and CNV data with SNP data.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.